ANX Financial Facts

Net loss: -10.71M
Total operating expenses: 10.22M
See Full Income Statement

Cash and cash equivalents: 24.49M
Total liabilities and stockholders' equity: 47.68M
See Full Balance Sheet

Adventrx Pharmaceuticals, Inc. (ANX) Earnings

  |   Expand Research on ANX
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate +25.0% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -24.2% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/5/12 Q312 -$0.07N/A N/A N/AN/A N/A Details
8/6/12 Q212 $0.09N/A N/A N/AN/A N/A Details
5/7/12 Q112 -$0.09N/A N/A N/AN/A N/A Details
3/7/12 Q411 -$0.06-$0.09 +$0.03N/AN/A N/A Details
11/7/11 Q311 -$0.13-$0.13 $0.00N/AN/A N/A Details
5/9/11 Q111 -$0.13-$0.26 +$0.13N/AN/A N/A Details
3/10/11 Q410 -$0.15-$0.18 +$0.03N/AN/A N/A Details